M
Mark R. Withers
Researcher at Kenya Medical Research Institute
Publications - 4
Citations - 515
Mark R. Withers is an academic researcher from Kenya Medical Research Institute. The author has contributed to research in topics: Malaria & Plasmodium falciparum. The author has an hindex of 4, co-authored 4 publications receiving 489 citations. Previous affiliations of Mark R. Withers include United States Army Medical Research Unit-Kenya.
Papers
More filters
Journal ArticleDOI
Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya.
Bernhards Ogutu,Odika J. Apollo,Denise McKinney,Willis Okoth,Joram Siangla,Filip Dubovsky,Kathryn Tucker,John N. Waitumbi,Carter L. Diggs,Janet Wittes,Elissa Malkin,Amanda J. Leach,Lorraine Soisson,Jessica Milman,Lucas Otieno,Carolyn A. Holland,Mark E. Polhemus,Shon Remich,Christian F. Ockenhouse,Joe Cohen,W. Ripley Ballou,Samuel K. Martin,Evelina Angov,V. Ann Stewart,Jeffrey A. Lyon,D. Gray Heppner,Mark R. Withers +26 more
TL;DR: FMP1/AS02 had a good safety profile and was well-tolerated but more reactogenic than the comparator, and is not a promising candidate for further development as a monovalent malaria vaccine.
Journal ArticleDOI
Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya.
José A. Stoute,Joash Gombe,Mark R. Withers,Joram Siangla,Denise McKinney,Melanie Onyango,James F. Cummings,Jessica Milman,Kathryn Tucker,Lorraine Soisson,V. Ann Stewart,Jeffrey A. Lyon,Evelina Angov,Amanda J. Leach,Joe Cohen,Kent E. Kester,Christian F. Ockenhouse,Carolyn A. Holland,Carter L. Diggs,Janet Wittes,D. Gray Heppner +20 more
TL;DR: The FMP1/AS02A vaccine is safe and immunogenic in adults and should progress to safety testing in children at greatest risk of malaria.
Journal ArticleDOI
Safety and Reactogenicity of an MSP-1 Malaria Vaccine Candidate: A Randomized Phase Ib Dose-Escalation Trial in Kenyan Children
Mark R. Withers,Mark R. Withers,Denise McKinney,Denise McKinney,Bernhards Ogutu,Bernhards Ogutu,John N. Waitumbi,John N. Waitumbi,Jessica Milman,Odika J. Apollo,Odika J. Apollo,Otieno G Allen,Otieno G Allen,Kathryn Tucker,Lorraine Soisson,Carter L. Diggs,Amanda J. Leach,Janet Wittes,Filip Dubovsky,V. Ann Stewart,Shon Remich,Shon Remich,Joe Cohen,W. Ripley Ballou,Carolyn A. Holland,Jeffrey A. Lyon,Evelina Angov,José A. Stoute,Samuel K. Martin,Samuel K. Martin,D. Gray Heppner +30 more
TL;DR: The FMP1/AS02A vaccine was safe and immunogenic in malaria-exposed 12- to 47-mo-old children and the magnitude of immune response of the 25 and 50 μg doses was superior to that of the 10 μg dose.
Journal ArticleDOI
Aeromedical evacuation of biological warfare casualties: a treatise on infectious diseases on aircraft.
TL;DR: It is concluded that, given adequate foresight, expertise, and resources, the AE of even contagious BW casualties could be safely and effectively accomplished.